Literature DB >> 21900905

PrEP trial successes prompt cost-effectiveness questions.

Roxanne Khamsi.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21900905     DOI: 10.1038/nm0911-1028b

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.

Authors:  Carel Pretorius; John Stover; Lori Bollinger; Nicolas Bacaër; Brian Williams
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

  1 in total
  1 in total

1.  Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020.

Authors:  Linda-Gail Bekker; Benjamin Brown; Dvora Joseph-Davey; Kathrine Gill; Michelle Moorhouse; Sinead Delany-Moretlwe; Landon Myer; Catherine Orrell; Kevin Rebe; W D Francois Venter; Carole L Wallis
Journal:  South Afr J HIV Med       Date:  2020-12-10       Impact factor: 2.744

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.